Is Trinity Biotech Stock a Good Investment?
Trinity Biotech Investment Advice | TRIB |
- Examine Trinity Biotech's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Trinity Biotech's leadership team and their track record. Good management can help Trinity Biotech navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Trinity Biotech's business and its evolving consumer preferences.
- Compare Trinity Biotech's performance and market position to its competitors. Analyze how Trinity Biotech is positioned in terms of product offerings, innovation, and market share.
- Check if Trinity Biotech pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Trinity Biotech's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Trinity Biotech plc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Trinity Biotech plc is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Trinity Biotech Stock
Researching Trinity Biotech's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 12.0% of the company outstanding shares are owned by corporate insiders. The company has Price/Earnings To Growth (PEG) ratio of 1.3. Trinity Biotech plc recorded a loss per share of 2.25. The entity last dividend was issued on the 5th of June 2015. The firm had 1:5 split on the 23rd of February 2024.
To determine if Trinity Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Trinity Biotech's research are outlined below:
| Trinity Biotech plc had very high historical volatility over the last 90 days | |
| Trinity Biotech plc has some characteristics of a very speculative penny stock | |
| Trinity Biotech plc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 56.83 M. Net Loss for the year was (24.02 M) with profit before overhead, payroll, taxes, and interest of 21.13 M. | |
| Trinity Biotech plc currently holds about 10.01 M in cash with (11.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Roughly 12.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Adsposure and Trinity Metro Expand Partnership with 75 New Bus Shelters |
Trinity Biotech Quarterly Long Term Debt |
|
Trinity Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Trinity Biotech plc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Trinity Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 4th of July 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Trinity Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Trinity Biotech's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-10-23 | 2018-09-30 | 0.06 | 0.05 | -0.01 | 16 | ||
2018-07-19 | 2018-06-30 | 0.06 | 0.07 | 0.01 | 16 | ||
2018-03-07 | 2017-12-31 | 0.07 | 0.08 | 0.01 | 14 | ||
2017-10-26 | 2017-09-30 | 0.07 | 0.06 | -0.01 | 14 | ||
2017-07-20 | 2017-06-30 | 0.06 | 0.07 | 0.01 | 16 | ||
2008-07-22 | 2008-06-30 | 0.08 | 0.07 | -0.01 | 12 | ||
2020-08-25 | 2020-06-30 | -0.02 | -0.036 | -0.016 | 80 | ||
2019-10-16 | 2019-09-30 | 0.06 | 0.04 | -0.02 | 33 |
Know Trinity Biotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Trinity Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Trinity Biotech plc backward and forwards among themselves. Trinity Biotech's institutional investor refers to the entity that pools money to purchase Trinity Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Integrys Wealth Advisors Llc | 2024-12-31 | 10 K | Hartland & Co | 2024-12-31 | 10 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.2 K | Rhumbline Advisers | 2024-12-31 | 1.8 K | Simplex Trading, Llc | 2024-12-31 | 1.4 K | Jones Financial Companies Lllp | 2024-12-31 | 468 | Bank Of America Corp | 2024-12-31 | 240 | Atlantic Trust Group, Llc | 2024-12-31 | 222 | Atwood & Palmer Inc | 2024-12-31 | 20.0 | Perceptive Advisors Llc | 2024-12-31 | 1.8 M | Hunter Associates Inc. | 2024-12-31 | 378.6 K |
Trinity Biotech's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.48 M.Market Cap |
|
Trinity Biotech's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.50) | (0.48) | |
| Return On Capital Employed | (0.55) | (0.52) | |
| Return On Assets | (0.36) | (0.35) | |
| Return On Equity | 0.90 | 0.95 |
Determining Trinity Biotech's profitability involves analyzing its financial statements and using various financial metrics to determine if Trinity Biotech is a good buy. For example, gross profit margin measures Trinity Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Trinity Biotech's profitability and make more informed investment decisions.
Please note, the presentation of Trinity Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Trinity Biotech's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Trinity Biotech's management manipulating its earnings.
Evaluate Trinity Biotech's management efficiency
Trinity Biotech plc has return on total asset (ROA) of (0.0819) % which means that it has lost $0.0819 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.1345) %, meaning that it created substantial loss on money invested by shareholders. Trinity Biotech's management efficiency ratios could be used to measure how well Trinity Biotech manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.95, whereas Return On Tangible Assets are projected to grow to (0.48). At present, Trinity Biotech's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 69.5 M, whereas Total Assets are forecasted to decline to about 64.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.14) | (0.13) | |
| Tangible Book Value Per Share | (0.30) | (0.29) | |
| Enterprise Value Over EBITDA | (14.67) | (15.41) | |
| Price Book Value Ratio | (0.79) | (0.75) | |
| Enterprise Value Multiple | (3.00) | (3.14) | |
| Price Fair Value | (0.79) | (0.75) | |
| Enterprise Value | 5.5 B | 3.9 B |
The operational strategies employed by Trinity Biotech management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 1.208 |
Basic technical analysis of Trinity Stock
As of the 24th of March, Trinity Biotech has the Risk Adjusted Performance of 0.0192, coefficient of variation of 8847.26, and Semi Deviation of 6.28. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Trinity Biotech plc, as well as the relationship between them.Trinity Biotech's Outstanding Corporate Bonds
Trinity Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Trinity Biotech plc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Trinity bonds can be classified according to their maturity, which is the date when Trinity Biotech plc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| TRINITY ACQUISITION PLC Corp BondUS89641UAC53 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Trinity Biotech's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Trinity Biotech's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0192 | |||
| Market Risk Adjusted Performance | 0.2412 | |||
| Mean Deviation | 5.18 | |||
| Semi Deviation | 6.28 | |||
| Downside Deviation | 7.33 | |||
| Coefficient Of Variation | 8847.26 | |||
| Standard Deviation | 11.45 | |||
| Variance | 131.19 | |||
| Information Ratio | 0.0163 | |||
| Jensen Alpha | 0.1543 | |||
| Total Risk Alpha | 0.9894 | |||
| Sortino Ratio | 0.0255 | |||
| Treynor Ratio | 0.2312 | |||
| Maximum Drawdown | 108.49 | |||
| Value At Risk | (8.11) | |||
| Potential Upside | 8.51 | |||
| Downside Variance | 53.69 | |||
| Semi Variance | 39.5 | |||
| Expected Short fall | (7.57) | |||
| Skewness | 4.89 | |||
| Kurtosis | 35.54 |
| Risk Adjusted Performance | 0.0192 | |||
| Market Risk Adjusted Performance | 0.2412 | |||
| Mean Deviation | 5.18 | |||
| Semi Deviation | 6.28 | |||
| Downside Deviation | 7.33 | |||
| Coefficient Of Variation | 8847.26 | |||
| Standard Deviation | 11.45 | |||
| Variance | 131.19 | |||
| Information Ratio | 0.0163 | |||
| Jensen Alpha | 0.1543 | |||
| Total Risk Alpha | 0.9894 | |||
| Sortino Ratio | 0.0255 | |||
| Treynor Ratio | 0.2312 | |||
| Maximum Drawdown | 108.49 | |||
| Value At Risk | (8.11) | |||
| Potential Upside | 8.51 | |||
| Downside Variance | 53.69 | |||
| Semi Variance | 39.5 | |||
| Expected Short fall | (7.57) | |||
| Skewness | 4.89 | |||
| Kurtosis | 35.54 |
Consider Trinity Biotech's intraday indicators
Trinity Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Trinity Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Trinity Biotech time-series forecasting models is one of many Trinity Biotech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Trinity Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Trinity Stock media impact
Far too much social signal, news, headlines, and media speculation about Trinity Biotech that are available to investors today. That information is available publicly through Trinity media outlets and privately through word of mouth or via Trinity internal channels. However, regardless of the origin, that massive amount of Trinity data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Trinity Biotech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Trinity Biotech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Trinity Biotech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Trinity Biotech alpha.
Trinity Biotech Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Trinity Biotech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Trinity Biotech Corporate Management
| Simon Dunne | Chief Officer | Profile | |
| Fernando Devia | Ex Sales | Profile | |
| Eibhlin Kelly | Chief Officer | Profile | |
| Aris Kekedjian | CEO Chairman | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trinity Biotech plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (2.25) | Revenue Per Share | Quarterly Revenue Growth 0.032 | Return On Assets |
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Trinity Biotech's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.